Oct 12 close
Enovis stock hit a 52-week low of $17.29 this week amid continued share price weakness, down 40.4% over the past year according to one report. Needham cut its price target on the stock from $52 to $34 while maintaining a Buy rating, citing the anticipated acquisition of eCential Robotics, which is expected to negatively impact adjusted EBITDA margin by approximately 150 basis points in 2027. Separately, Enovis announced it will host its third-quarter 2026 results conference call on 5 November, and a transcript of the Q2 2026 call highlighted 5% organic growth driven by the Recon and P&R segments, the commercial launch of Arvis, and reaffirmed full-year guidance despite expected Q3 seasonality and geopolitical impacts.
The stock closed at $18.25, up 3.2%, but remains below both its 50-day average of $21.72 and 200-day average of $23.53, with the 50-day below the 200-day. The GekkoIndex reads 64.2, placing it in the Accumulation zone. Price sits 33.7% below Gekko Fair Value of $27.54.
Enovis reports third-quarter results on 5 November, 24 days away, falling inside a typical 20-trading-day hold and historically producing an average absolute reaction of 9.7%. Over the last 90 days there have been 3 open-market insider purchases totaling $399,652. Seasonality from this point in the calendar has averaged a 20-trading-day return of 8.3% over 5 years, rising in 3 of them. Analyst coverage includes 10 buy ratings and 1 hold among 11 firms, with a consensus target of $37.58.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Enovis scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $18.25 is below the 50-day ($21.72) and 200-day ($23.53) averages, and the 50-day is below the 200-day.
See the chart64.2, Accumulation
Reading 64.2 is in the Accumulation zone.
See the GekkoIndex33.7% below
Price is 33.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 3 open-market insider purchases.
See smart moneyReports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings+8.3% on average
From this point in the calendar, the next 20 trading days averaged +8.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Enovis closed at $18.25 on Oct 12, 2026, −41.8% over the past year, inside a 52-week range of $16.70 to $34.28.
Use the left and right arrow keys to read daily values.
Put ENOV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Enovis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.2, in the Accumulation zone, down 0.4 points over five sessions.
Down 0.4 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 69 | −0.5% | +0.9% | ||
| Accumulation (current zone) | 296 | +0.5% | −1.0% | ||
| Neutral | 307 | −1.8% | −5.4% | ||
| Distribution | 9 | Too few readings yet | |||
| Selling | 1 | Too few readings yet | |||
Average ENOV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Enovis trades 33.7% below Gekko Fair Value of $27.54, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Enovis shares are worth, recalculated every trading day.
$27.54
Gekko Fair Value, Oct 10, 2026
33.7% Undervalued
At the end of Aug 2026 the price was 30.8% below the estimate.
Insiders filed 3 open-market purchases in Enovis worth $400K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$400Kin 3 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 8 | Engert Oliver officer: Chief Administrative Officer | Purchase | $50K |
| Sep 4 | McDonald Damien director, officer: Chief Executive Officer | Purchase | $250K |
| Sep 4 | Engert Oliver officer: Chief Administrative Officer | Purchase | $100K |
From Form 4 filings, dated to when each was filed.
No trades in ENOV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Enovis has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold ENOV.
Enovis reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 7 of its last 8 reports.
Nov 5, 2026
Expected before the open, 24 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.90 est $0.85 | $582.8M est $581.8M | −11.8% |
| May 7, 2026 | $0.89 est $0.81 | $589.2M est $572.0M | +6.7% |
| Feb 26, 2026 | $0.95 est $0.81 | $575.8M est $582.9M | +14.1% |
| Nov 6, 2025 | $0.75 est $0.67 | $548.9M est $584.3M | −10.9% |
| Aug 7, 2025 | $0.79 est $0.74 | $564.5M est $538.6M | +10.4% |
| May 8, 2025 | −$0.98 est $0.74 | $558.8M est $551.1M | −3.5% |
| Feb 26, 2025 | $0.98 est $0.92 | $561.0M est $547.8M | −9.5% |
| Nov 6, 2024 | $0.73 est $0.62 | $505.2M est $555.4M | +10.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Enovis is $37.58, +105.9% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Needham | $34 | +86.3% |
| Oct 5 | UBS | $44 | +141.1% |
| Sep 8 | Wells Fargo | $33 | +80.8% |
| Sep 2 | Citizens JMP | $47 | +157.5% |
| Sep 2 | Wells Fargo | $33 | +80.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Enovis averaged +8.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.2% | 4 of 5 |
| Next 10 trading days | +3.4% | 4 of 5 |
| Next 15 trading days | +5.0% | 4 of 5 |
| Next 20 trading days | +8.3% | 3 of 5 |
| Next 30 trading days | +8.2% | 4 of 5 |
For scale, ENOV’s typical 20-trading-day move in either direction is about 7.7%.
Enovis’s market cap is $1.05B and revenue of $2.30B over the last twelve months.
Coverage of Enovis this week reads negative: 2 positive, 3 neutral and 5 negative headlines.
Enovis’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Enovis’s market cap is $1.05B at the Oct 12, 2026 close of $18.25, with 57.67M shares outstanding.
The consensus analyst 12-month price target for Enovis is $37.58, +105.9% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Enovis is undervalued: the Oct 12, 2026 close of $18.25 is 33.7% below Gekko Fair Value of $27.54. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Enovis is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of $0.77 per share on revenue of $557.1M. Enovis beat the earnings estimate in 7 of its last 8 reports, moving 9.7% on average across the report.
Enovis’s 52-week high is $34.28 and its 52-week low is $16.70; it closed at $18.25 on Oct 12, 2026, −41.8% over the past year. Over the last five years the shares peaked at $94.10 on Nov 5, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.